Crossover study comparing bioavailability of a capsule formulation of the glucagon receptor antagonist LGD-6972 to an oral solution formulation in healthy subjects

被引：0
|
作者：
Pipkin, J. D. [1 ]
Vajda, E. [1 ]
Biernat, L. [2 ]
Klein, D. J. [2 ]
Li, Y. -X. [2 ]
Zangmeister, M. [2 ]
Zhou, R. [2 ]
Zhi, L. [1 ]
Marschke, K. [1 ]
机构：
[1] Ligand Pharmaceut Inc, San Diego, CA USA
[2] Medpace Inc, Cincinnati, OH USA
来源：
DIABETOLOGIA | 2017年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
863
引用
收藏
页码：S399 / S400
页数：2
相关论文
共 50 条
  • [1] Pharmacokinetics of the Glucagon Receptor Antagonist LGD-6972
    Vajda, Eric G.
    Plotkin, Diane J.
    Logan, Douglas
    Li, Yong-Xi
    Pipkin, J. D.
    Zhi, Lin
    Marschke, Keith B.
    DIABETES, 2014, 63 : A290 - A290
  • [2] An Allosteric Glucagon Receptor Antagonist, LGD-6972, Displays Biased Receptor Signaling
    Vajda, Eric G.
    Zhi, Lin
    Marschke, Keith
    DIABETES, 2018, 67
  • [3] Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD-6972 in healthy subjects and subjects with type 2 diabetes mellitus
    Vajda, Eric G.
    Logan, Douglas
    Lasseter, Kenneth
    Armas, Danielle
    Plotkin, Diane J.
    Pipkin, J. D.
    Li, Yong-Xi
    Zhou, Rong
    Klein, David
    Wei, Xiaoxiong
    Dilzer, Stacy
    Zhi, Lin
    Marschke, Keith B.
    DIABETES OBESITY & METABOLISM, 2017, 19 (01): : 24 - 32
  • [4] Glucagon Receptor Antagonist LGD-6972 Is Efficacious in Streptozotocin-Induced Diabetic Mice
    Vajda, Eric G.
    Zhi, Lin
    Marschke, Keith B.
    DIABETES, 2013, 62 : A290 - A290
  • [5] Pharmacokinetics and Pharmacodynamics of the Glucagon Receptor Antagonist LGD-6972 in a Multi-dose Clinical Trial
    Vajda, Eric G.
    Logan, Douglas
    Lasseter, Kenneth
    Armas, Danielle
    Plotkin, Diane
    Pipkin, J. D.
    Li, Yong-Xi
    Zhou, Rong
    Klein, David
    Wei, Xiaoxiong
    Dilzer, Stacy
    Zhi, Lin
    Marschke, Keith B.
    DIABETES, 2015, 64 : A308 - A308
  • [6] LGD-6972, a Potent, Orally-Bioavailable, Small Molecule Glucagon Receptor Antagonist for the Treatment of Type 2 Diabetes
    Vajda, Eric G.
    Potter, Scott C.
    Fujitaki, James M.
    Reddy, Raja K.
    Van Poelje, Paul D.
    Lee, Yong-Hee
    Henderson, Ian
    Zhi, Lin
    Marschke, Keith B.
    DIABETES, 2012, 61 : A252 - A252
  • [7] Setipiprant, a Selective Oral Antagonist of Human CRTH2: Relative Bioavailability of a Capsule and a Tablet Formulation in Healthy Female and Male Subjects
    Baldoni, Daniela
    Mackie, Alison
    Gutierrez, Marcelo
    Theodor, Rudolf
    Dingemanse, Jasper
    CLINICAL THERAPEUTICS, 2013, 35 (11) : 1842 - 1848
  • [8] THE BIOAVAILABILITY OF AN ORAL LIQUID FORMULATION (OLF) RELATIVE TO A FORMULATED CAPSULE (FC) OF CRIZOTINIB, A DUAL ALK/MET INHIBITOR, IN HEALTHY SUBJECTS
    Xu, H.
    O'Gorman, M.
    Tan, W.
    Leister, C.
    Monajati, M.
    Brega, N.
    Ni, G.
    Phillips, S.
    da Costa, L. Mendes
    Bello, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S23 - S23
  • [9] Bioavailability Study of a Transdermal Patch Formulation of Rivastigmine Compared with Exelon in Healthy Subjects
    Adelaida Morte
    Anna Vaqué
    Marc Iniesta
    Barbara Schug
    Cornelius Koch
    Rafael De la Torre
    Bjoern Schurad
    European Journal of Drug Metabolism and Pharmacokinetics, 2022, 47 : 567 - 578
  • [10] Bioavailability Study of a Transdermal Patch Formulation of Rivastigmine Compared with Exelon in Healthy Subjects
    Morte, Adelaida
    Vaque, Anna
    Iniesta, Marc
    Schug, Barbara
    Koch, Cornelius
    De la Torre, Rafael
    Schurad, Bjoern
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2022, 47 (04) : 567 - 578
12345